Shire plc Sustainability Profile
Shire plc, a leading global biotechnology company headquartered in Ireland (IE), focuses on developing innovative therapies for rare diseases and complex conditions. Founded in 1986, Shire has established a strong presence in key operational regions, including North America, Europe, and Asia. Specialising in areas such as neuroscience, immunology, and genetic disorders, Shire is renowned for its unique portfolio of products, including treatments for attention deficit hyperactivity disorder (ADHD) and rare genetic conditions. The company has achieved significant milestones, including numerous FDA approvals and a robust pipeline of therapies that address unmet medical needs. With a commitment to improving patient outcomes, Shire plc has solidified its position as a market leader in the biotechnology sector, recognised for its dedication to innovation and excellence in healthcare.
DitchCarbon Score
How does Shire plc's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shire plc's score of 55 is higher than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shire plc's reported carbon emissions
In 2016, Shire plc reported total carbon emissions of approximately 83,119,000 kg CO2e. This figure includes Scope 1 emissions of about 26,234,000 kg CO2e, Scope 2 emissions of approximately 118,000,000 kg CO2e, and Scope 3 emissions of around 34,078,000 kg CO2e. The combined Scope 1 and 2 emissions totalled about 49,041,000 kg CO2e. Shire plc does not currently have specific reduction targets or initiatives documented, nor are there any commitments to the Science Based Targets initiative (SBTi) or other climate pledges. The emissions data is cascaded from its parent company, Takeda Pharmaceutical Company Limited, indicating a corporate family relationship that influences its climate strategy. As a current subsidiary of Takeda, Shire's climate commitments may align with broader initiatives undertaken by its parent company, although specific details on these initiatives are not provided in the available data.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | |
|---|---|
| Scope 1 | 26,234,000 |
| Scope 2 | 118,000,000 |
| Scope 3 | 34,078,000 |
How Carbon Intensive is Shire plc's Industry?
How Carbon Intensive is Shire plc's Location?
Shire plc's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Shire plc has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
